{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:33:01Z","timestamp":1790875981532,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2006,9,14]],"date-time":"2006-09-14T00:00:00Z","timestamp":1158192000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2007,2,2]]},"DOI":"10.1007\/s10067-006-0378-z","type":"journal-article","created":{"date-parts":[[2006,9,13]],"date-time":"2006-09-13T16:15:09Z","timestamp":1158164109000},"page":"393-400","source":"Crossref","is-referenced-by-count":7,"title":["Elevated levels of soluble Fas (APO-1, CD95), soluble Fas ligand, and matrix metalloproteinase-3 in sera from patients with active untreated adult onset Still\u2019s disease"],"prefix":"10.1007","volume":"26","author":[{"given":"Der-Yuan","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joung-Liang","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang-Ju","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsu-Yi","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2006,9,14]]},"reference":[{"key":"378_CR1","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1136\/ard.30.2.121","volume":"30","author":"EGL Bywaters","year":"1971","unstructured":"Bywaters EGL (1971) Still\u2019s disease of adults. Ann Rheum Dis 30:121\u2013133","journal-title":"Ann Rheum Dis"},{"key":"378_CR2","first-page":"1139","volume":"14","author":"A Ohta","year":"1987","unstructured":"Ohta A, Yamaguchi M, Kaneoka H, Nagayoshi T, Hiida M (1987) Adult Still\u2019s disease: review of 228 cases from the literature. J Rheumatol 14:1139\u20131146","journal-title":"J Rheumatol"},{"key":"378_CR3","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1136\/ard.2003.013680","volume":"63","author":"DY Chen","year":"2004","unstructured":"Chen DY, Lan JL, Lin FJ, Hsieh TY, Wen MC (2004) A predominance of Th1 cytokine in peripheral blood and pathological tissues of patients with active untreated adult-onset Still\u2019s disease. Ann Rheum Dis 63:1300\u20131306","journal-title":"Ann Rheum Dis"},{"key":"378_CR4","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1093\/intimm\/6.10.1545","volume":"6","author":"F Ramsdell","year":"1994","unstructured":"Ramsdell F, Seaman MS, Miller RE, Picha KS, Kennedy MK, Lynch DH (1994) Differential ability of Th1 and Th2 cells to express Fas ligand and to undergo activation-induced cell death. Int Immunol 6:1545\u20131553","journal-title":"Int Immunol"},{"key":"378_CR5","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1084\/jem.185.10.1837","volume":"185","author":"X Zhang","year":"1997","unstructured":"Zhang X, Brunner T, Carter L, Dutton RW, Rogers P, Bradley L et al (1997) Unequal death in T helper cell (Th)1 and Th2 effectors: Th1, but not Th2, effectors undergo rapid Fas\/FasL-mediated apoptosis. J Exp Med 185:1837\u20131849","journal-title":"J Exp Med"},{"key":"378_CR6","first-page":"2189","volume":"31","author":"DY Chen","year":"2004","unstructured":"Chen DY, Lan JL, Lin FJ, Hsieh TY (2004) Proinflammatory cytokine profiles in the sera and in the pathological tissues of patients with active untreated adult onset Still\u2019s disease. J Rheumatol 31:2189\u20132198","journal-title":"J Rheumatol"},{"key":"378_CR7","first-page":"2422","volume":"30","author":"JH Choi","year":"2003","unstructured":"Choi JH, Suh CH, Lee YM, Suh YJ, Lee SK, Kim SS et al (2003) Serum cytokine profiles in patients with adult onset Still\u2019s disease. J Rheumatol 30:2422\u20132427","journal-title":"J Rheumatol"},{"key":"378_CR8","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/1529-0131(200103)44:3<550::AID-ANR103>3.0.CO;2-5","volume":"44","author":"M Kawashima","year":"2001","unstructured":"Kawashima M, Yamamura M, Taniai M, Yamauchi H, Tanimoto T, Kurimoto M et al (2001) Levels of interleukin-18 and its binding inhibitors in the blood circulation of patients with adult-onset Still\u2019s disease. Arthritis Rheum 44:550\u2013560","journal-title":"Arthritis Rheum"},{"issue":"5A","key":"378_CR9","first-page":"3253","volume":"17","author":"T Ohtsuki","year":"1997","unstructured":"Ohtsuki T, Micallef MJ, Kohno K, Tanimoto T, Ikeda M, Kurimoto M (1997) Interleukin 18 enhances Fas ligand expression and induces apoptosis in Fas-expressing human myelomonocytic KG-1 cells. Anticancer Res 17(5A):3253\u20133258","journal-title":"Anticancer Res"},{"key":"378_CR10","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1126\/science.7533326","volume":"267","author":"S Nagata","year":"1995","unstructured":"Nagata S, Golstein P (1995) The Fas death factor. Science 267:1449\u20131456","journal-title":"Science"},{"key":"378_CR11","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1126\/science.280.5361.243","volume":"280","author":"L Parijs Van","year":"1998","unstructured":"Van Parijs L, Abbas Ak (1998) Homeostasis and self-tolerance in the immune system: turning lymphocytes off. Science 280:243\u2013248","journal-title":"Science"},{"key":"378_CR12","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1191\/096120301680416977","volume":"10","author":"M Funauchi","year":"2001","unstructured":"Funauchi M, Sugiyama M, SukYoo B, Ikoma S, Ohno M, Kinoshita K et al (2001) A possible role of apoptosis for regulating autoreactive response in systemic lupus erythematosus. Lupus 10:284\u2013288","journal-title":"Lupus"},{"key":"378_CR13","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0092-8674(00)81874-7","volume":"88","author":"S Nagata","year":"1997","unstructured":"Nagata S (1997) Apoptosis by death factor. Cell 88:355\u2013365","journal-title":"Cell"},{"key":"378_CR14","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/0092-8674(93)90326-L","volume":"75","author":"T Suda","year":"1993","unstructured":"Suda T, Takahasi T, Golstain P, Nagata S (1993) Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 75:1169\u20131178","journal-title":"Cell"},{"key":"378_CR15","doi-asserted-by":"crossref","first-page":"3806","DOI":"10.4049\/jimmunol.154.8.3806","volume":"154","author":"T Suda","year":"1995","unstructured":"Suda T, Okazaki T, Naito Y, Yokota T, Arai N, Ozaki S et al (1995) Expression of the Fas ligand in cells of T cell lineage. J Immunol 154:3806\u20133813","journal-title":"J Immunol"},{"key":"378_CR16","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/373444a0","volume":"373","author":"ST Ju","year":"1995","unstructured":"Ju ST, Panka DJ, Cui H, Ettinger R, El-Khatib M, Sherr DH et al (1995) Fas (CD95)\/FasL interactions required for programmed cell death after T-cell activation. Nature 373:444\u2013448","journal-title":"Nature"},{"key":"378_CR17","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0167-5699(95)80069-7","volume":"16","author":"S Nagata","year":"1995","unstructured":"Nagata S, Suda T (1995) Fas and Fas ligand: lpr and gld mutations. Immunol Today 16:39\u201343","journal-title":"Immunol Today"},{"key":"378_CR18","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1002\/art.1780400610","volume":"40","author":"RM Ito","year":"1997","unstructured":"Ito RM, Terasaki S, Itoh J, Katoh H, Yonehara S, Nose M et al (1997) Rheumatic diseases in an MRL strain of mice with a deficit in the functional Fas ligand. Arthritis Rheum 40:1054\u20131063","journal-title":"Arthritis Rheum"},{"key":"378_CR19","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/356314a0","volume":"356","author":"R Watanabe-Fukunaga","year":"1992","unstructured":"Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S (1992) Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356:314\u2013317","journal-title":"Nature"},{"key":"378_CR20","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1182\/blood.V89.4.1341","volume":"89","author":"MC Sneller","year":"1997","unstructured":"Sneller MC, Wang J, Dale JK, Strober W, Middelton LA, Choi Y et al (1997) Clinical, immunologic, and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis. Blood 89:1341\u20131348","journal-title":"Blood"},{"key":"378_CR21","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1006\/clin.1996.0136","volume":"80","author":"JD Mountz","year":"1996","unstructured":"Mountz JD, Zhou T, Su X, Wu J, Cheng J (1996) The role of programmed cell death as autoimmune disease. Clin Immunol Immunopathol 80:S2\u2013S14","journal-title":"Clin Immunol Immunopathol"},{"key":"378_CR22","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0002-9343(99)00332-0","volume":"108","author":"T Grodzicky","year":"2000","unstructured":"Grodzicky T, Elkon KB (2000) Apoptosis in rheumatic diseases. Am J Med 108:73\u201382","journal-title":"Am J Med"},{"key":"378_CR23","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.4049\/jimmunol.156.12.4622","volume":"156","author":"G Papoff","year":"1996","unstructured":"Papoff G, Cascino I, Eramo A, Starace G, Lynch DH, Ruberti G (1996) An N-terminal domain shared by Fas\/Apo-1 (CD95) soluble variants prevent cell death in vitro. J Immunol 156:4622\u20134630","journal-title":"J Immunol"},{"key":"378_CR24","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1126\/science.7510905","volume":"263","author":"J Cheng","year":"1994","unstructured":"Cheng J, Zhou T, Liu C (1994) Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 263:1759\u20131762","journal-title":"Science"},{"key":"378_CR25","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s102380200002","volume":"2","author":"F Silvestris","year":"2002","unstructured":"Silvestris F, Williams RC, Calvani N, Grinello D, Tucci M, Cafforio P et al (2002) Serum elevations of soluble Fas (CD95\/Apo-1) concur in deregulating T cell apoptosis during active lupus disease. Clin Exp Med 2:13\u201327","journal-title":"Clin Exp Med"},{"key":"378_CR26","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1084\/jem.182.6.1777","volume":"182","author":"N Kayagaki","year":"1995","unstructured":"Kayagaki N, Kawasaki A, Ebata T, Ohmoto H, Ikeda S, Inoue K et al (1995) Metalloproteinase-mediated release of human Fas ligand. J Exp Med 182:1777","journal-title":"J Exp Med"},{"key":"378_CR27","first-page":"22","volume":"28","author":"H Matsuno","year":"2001","unstructured":"Matsuno H, Yudoh K, Watanabe Y, Nakazawa F, Aono H, Kimura T (2001) Stromelysin-1 (MMP-3) in synovial fluid of patients with rheumatoid arthritis has potential to cleave membrane bound Fas ligand. J Rheumatol 28:22\u201328","journal-title":"J Rheumatol"},{"key":"378_CR28","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1002\/j.1460-2075.1995.tb07096.x","volume":"14","author":"M Tanaka","year":"1995","unstructured":"Tanaka M, Suda T, Takahasi T, Nagata S (1995) Expression of the functional soluble form of human Fas ligand in activated lymphocyte. EMBO J 14:1129\u20131136","journal-title":"EMBO J"},{"key":"378_CR29","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1002\/art.1780400617","volume":"40","author":"K Nozawa","year":"1997","unstructured":"Nozawa K, Kayagaki N, Tokano Y, Yagita H, Okumura K, Hasimoto H (1997) Soluble Fas (APO-1, CD95) and soluble Fas ligand in rheumatic diseases. Arthritis Rheum 40:1126\u20131129","journal-title":"Arthritis Rheum"},{"key":"378_CR30","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1023\/A:1016040925295","volume":"22","author":"M Christensson","year":"2002","unstructured":"Christensson M, Pettersson E, Eneslatt K, Christensson B, Bratt J, Rantapaa-Dahlqvist S et al (2002) Serum sFas levels are elevated in ANCA-positive vasculitis compared with other autoimmune diseases. J Clin Immunol 22:220\u2013227","journal-title":"J Clin Immunol"},{"key":"378_CR31","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/(SICI)1096-8652(200006)64:2<116::AID-AJH8>3.0.CO;2-8","volume":"64","author":"U Emmenegger","year":"2000","unstructured":"Emmenegger U, Zehnder R, Frey U, Reimers A, Spaeth PJ, Neftel KA (2000) Elevation of soluble Fas and soluble Fas ligand in reactive macrophage activation syndromes. Am J Hematol 64:116\u2013119","journal-title":"Am J Hematol"},{"key":"378_CR32","first-page":"424","volume":"19","author":"M Yamaguchi","year":"1992","unstructured":"Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi S et al (1992) Preliminary criteria for classification of adult Still\u2019s disease. J Rheumatol 19:424\u2013430","journal-title":"J Rheumatol"},{"key":"378_CR33","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/00005792-199103000-00004","volume":"70","author":"J Pouchot","year":"1991","unstructured":"Pouchot J, Sampalis JS, Beaudet F, Carette S, Decary F, Salusinsky-Sternbach M et al (1991) Adult Still\u2019s disease: manifestations, disease course, and outcome in 62 patients. Medicine 70:118\u2013136","journal-title":"Medicine"},{"key":"378_CR34","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA et al (1988) The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315\u2013324","journal-title":"Arthritis Rheum"},{"key":"378_CR35","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.3748\/wjg.v10.i21.3151","volume":"10","author":"NL Li","year":"2004","unstructured":"Li NL, Nie H, Yu QW, Zhang JY, Ma AL, Shen BH et al (2004) Role of soluble Fas ligand in autoimmune diseases. World J Gastroenterol 10:3151\u20133156","journal-title":"World J Gastroenterol"},{"key":"378_CR36","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1084\/jem.186.12.2045","volume":"186","author":"T Suda","year":"1997","unstructured":"Suda T, Hashimoto H, Tanaka M, Ochi T, Nagata S (1997) Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J Exp Med 186:2045\u20132050","journal-title":"J Exp Med"},{"key":"378_CR37","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/08916930290005882","volume":"35","author":"S Kim","year":"2002","unstructured":"Kim S, Kim JY, Lee TH, Suk K, Cha HS, Koh EM et al (2002) Soluble Fas ligand-susceptible \u201cmemory\u201d cells in human but not in mice: potential role of soluble Fas ligand in deletion of auto-reactive cells. Autoimmunity 35:15\u201320","journal-title":"Autoimmunity"},{"key":"378_CR38","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1126\/science.282.5394.1714","volume":"282","author":"JJ Chen","year":"1998","unstructured":"Chen JJ, Sun Y, Nabel GJ (1998) Regulation of the proinflammatory effects of Fas ligand (CD95L). Science 282:1714\u20131717","journal-title":"Science"},{"key":"378_CR39","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1097\/01.LAB.0000101703.80133.99","volume":"83","author":"P Szodoray","year":"2003","unstructured":"Szodoray P, Jellestad S, Nakken B, Brun JG, Jonsson R (2003) Programmed cell death in rheumatoid arthritis peripheral blood T-cell subpopulations determined by laser scanning cytometry. Lab Invest 83:1839\u20131848","journal-title":"Lab Invest"},{"key":"378_CR40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/1529-0131(199801)41:1<1::AID-ART1>3.0.CO;2-V","volume":"41","author":"K Nishioka","year":"1998","unstructured":"Nishioka K, Hasusuma T, Kato T, Sumida T, Kobata T (1998) Apoptosis in rheumatoid arthritis: a novel pathway in the regulation of synovial tissue. Arthritis Rheum 41:1\u20139","journal-title":"Arthritis Rheum"},{"key":"378_CR41","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/1096-9896(2000)9999:9999<::AID-PATH746>3.0.CO;2-K","volume":"193","author":"CT Chou","year":"2001","unstructured":"Chou CT, Yang JS, Lee MR (2001) Apoptosis in rheumatoid arthritis-expression of Fas, Fas-L, p53, and Bcl-2 in rheumatoid synovial tissues. J Pathol 193:110\u2013116","journal-title":"J Pathol"},{"key":"378_CR42","volume-title":"Textbook of rheumatology","author":"A Werb","year":"1993","unstructured":"Werb A, Alexander CM (1993) Proteinases and matric degradation. In: Kelley WN, Harris ED, Ruddy S, Sledge CB (eds) Textbook of rheumatology, 4th edn. Saunders, Philadelphia","edition":"4"},{"key":"378_CR43","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/rheumatology\/keg037","volume":"42","author":"MJ Green","year":"2003","unstructured":"Green MJ, Gough AKS, Devlin J, Smith J, Astin P, Taylor D et al (2003) Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis. Rheumatology 42:83\u201388","journal-title":"Rheumatology"},{"key":"378_CR44","first-page":"10","volume":"30","author":"A Katrib","year":"2003","unstructured":"Katrib A, Smith MD, Ahern MJ, Slavotinek J, Stafford L, Cuello C et al (2003) Reduced chemokine and matrix metalloproteinase expression in patients with rheumatoid arthritis achieving remission. J Rheumatol 30:10\u201321","journal-title":"J Rheumatol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-006-0378-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-006-0378-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-006-0378-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T21:00:32Z","timestamp":1683579632000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-006-0378-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9,14]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,2,2]]}},"alternative-id":["378"],"URL":"https:\/\/doi.org\/10.1007\/s10067-006-0378-z","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,9,14]]}}}